Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.60 |
| ▸ | PDE4A | P27815 | 11/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875839 | 1.00 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| Hydrochloric Acid SCHEMBL4357313 | 0.99 | PDE4D (0.59) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| Hydrochloric Acid SCHEMBL5559987 | 0.90 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| SCHEMBL2886875 | 0.88 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| SCHEMBL5875874 | 0.88 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| Hydrochloric Acid SCHEMBL4011677 | 0.88 | PDE4D (0.62) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| SCHEMBL5958810 | 0.87 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4011641 | 0.85 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| SCHEMBL2881703 | 0.84 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CPDE7B | |
| SCHEMBL6435630 | 0.84 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CPDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | claimed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| WO-2004098633-A1 | COMPOSITION COMPRISING A PDE-4 INHIBITOR AND A TNF ALPHA ANTAGONIST | ALTANA PHARMA AG (DE) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098606-A1 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND SHUIL-1R II | ALTANA PHARMA AG (DE) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098578-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A TNF-ALFA ANTAGONIST SELECTED FROM INFLIXIMAB, ADALIMUMAB, CDP870 AND CDP517 | ALTANA PHARMA AG (DE) | 2004-11-18 | — | — | WO | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | PDE4D 9/4885PDE4A 3/4885PDE4B 4/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4D 1307/4885PDE4A 1173/4885PDE4B 1204/4885 |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | PDE4D 9/4885PDE4A 2/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.